A Study of Lower Dose Radiation Therapy for People With Prostate Cancer

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorMemorial Sloan Kettering Cancer Center

About this trial

The purpose of this study is to see whether giving a lower (de-escalated) dose of radiation therapy to some parts of the prostate can reduce side effects compared to giving the same (uniform) dose of radiation therapy to the whole prostate.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Documentation of Disease

Definition of Disease

Grade Group (GG) 1, 2, or 3.

PSA less than 20 ng/mL prior to starting ADT, if used.

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • MR-guided Stereotactic Body Radiation Therapy

    Radiation

    MR-guided 2 fraction Stereotactic Body Radiation Therapy

Treatment groups

54 Participants
are divided into 2 treatment groups
Group A: Group 1: Uniform dose SBRTActive comparator 1 intervention
Group B: Group 2: De-escalated dose SBRTExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Number of participants with acute GU toxicities

To estimate the absolute and relative risk of acute GU toxicity (CTCAE v5) when delivering dose de-escalated or uniform dose prostate SBRT, both using a 2-fraction regimen.

Time frame
12 weeks from the start of radiation therapy

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.